Full-Time

Senior Scientific Director

Flow Cytometry

Precision AQ

Precision AQ

501-1,000 employees

Data-driven drug access and launches

Compensation Overview

$203.2k - $304.8k/yr

+ Annual bonus

Frederick, MD, USA

In Person

PhD

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Quality Assurance (QA)
Data Analysis
Excel/Numbers/Sheets

Get referred to Precision AQ

See people who can refer or advise you

Requirements
  • A PhD in life sciences or a relevant field in life sciences and at least 18 years of full-time relevant laboratory experience, or an equivalent combination of education and experience.
  • At least 10 years of management experience.
  • A solid understanding of current Good Practice (GxP), College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), or International Organization for Standardization (ISO) standards.
  • Previous work experience in Good Laboratory Practice (GLP), Good Clinical Laboratory Practice (GCLP), or Clinical Laboratory Improvement Amendments (CLIA) regulatory compliance.
  • Expert-level human Flow Cytometry assay experience.
  • Experience handling sample types such as plasma, serum, and peripheral blood mononuclear cells (PBMCs).
  • Experience developing flow cytometry panels on fresh and fixed cells.
  • A solid understanding of current method validation standards.
  • The ability to organize and analyze data and prepare reports.
  • Strong computational skills, preferably with experience using Word, Excel, PowerPoint, Gen5, and GraphPad Prism.
  • The ability to exercise judgment and discretion.
  • The ability to work extended hours occasionally to meet business demands.
  • The ability to lift and carry between 1 and 15 pounds and lift up to 50 pounds overhead with assistance; frequent sitting, grasping, and right- or left-finger dexterity are required, and the role may involve exposure to freezer temperatures ranging from -20°C to -196°C.
  • The ability to read, write, speak fluently, and comprehend English.
Responsibilities
  • Lead development and validation efforts for Flow Cytometry assays supporting clinical and non-clinical studies.
  • Use scientific expertise to guide assay development and troubleshooting.
  • Train and mentor staff to ensure scientific rigor.
  • Engage with Quality Assurance to maintain regulatory compliance and work with project managers to ensure timely and efficient client communication.
  • Serve as Head of the laboratory, with responsibility for scientific activities, regulatory compliance, staff, and metrics associated with clients and product delivery.
  • Mentor and lead scientific staff assigned to Flow Cytometry assays, including receptor occupancy and internal and external cellular markers.
  • Ensure proper method development and validation so projects are quality-driven and executed against communicated timelines and milestones.
  • Direct scientific staff to ensure consistent scientific standards and compliance with company procedures and regulatory expectations on projects and client studies.
  • Participate in the Flow Cytometry community to keep the organization aware of relevant regulatory guidance.
  • Serve as Technical Lead and subject-matter expert for Flow Cytometry assay projects.
  • Serve as Project Director or Principal Investigator as required.
  • Lead the scientific team in designing and executing experiments, ensuring data is accurately analyzed, quality-driven, and delivered to clients on time.
  • Communicate with clients to ensure product delivery meets client expectations for Flow Cytometry assay projects.
  • Lead the team in establishing, writing, reviewing, and improving standard operating procedures, study protocols and plans, assay validation and verification documents, and associated reports.
  • Identify, update, and implement emerging laboratory techniques and instrumentation.
  • Collaborate with other technical teams on resource sharing and provide technical expertise.
  • Write and prepare abstracts, techniques, and draft scientific papers.
  • Present completed work at scientific meetings and in publications when appropriate.
  • Troubleshoot and correct routine scientific issues and problems in a timely manner.
  • Act as a scientific resource for external clients and internal Product and Services or Research and Development projects.
  • Assist with writing, reviewing, and editing contract and grant applications and proposals.
  • Maintain and support safe laboratory practices and the laboratory environment.
  • Carry out other assigned duties and projects.
Desired Qualifications
  • Experience using Word, Excel, PowerPoint, Gen5, and GraphPad Prism.
  • Experience hosting or participating in regulatory audits.

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Get referred to Precision AQ

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Precision AQ says it serves all 30 top pharma companies and launched 450-plus drugs.
  • April 25, 2025 oncology hires sharpen payer, provider, and formulary strategy for launches.
  • May 28, 2026 ASCO materials showcase OncoGenius and Navigator365 Matrix with 100-plus cancer centers.

What critics are saying

  • IQVIA, ICON, and Syneos Health crowd Precision AQ’s commercialization niche globally.
  • AI patient-services commoditization from Phluence-style tools compresses consulting margins by 2027.
  • Reliance on pharma launch budgets creates existential exposure if one major client insources access strategy.

What makes Precision AQ unique

  • Precision AQ’s AET has 25-plus former access decision-makers, built since 2009.
  • February 17, 2026 hires Emma Hawe and Yahya Anvar deepen HEOR, AI, and EU reach.
  • November 18, 2025 Phluence investment extends agentic post-Rx automation beyond traditional HUB models.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Parental Leave

Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...